Stock Watch: Defeat Is The Mother Of Reinvention
Not All Change Is Good... And Strategic Contagion Can Compound Errors
Companies that are successful do not need to change their name, therapeutic area or product focus.
You may also be interested in...
After reporting sliding sales for both generics and complex generics in Q1, Viatris has nevertheless reaffirmed its commitment to the off-patent sector, highlighting in particular a planned launch this year of its Breyna rival to Symbicort.
Alvotech has received a further complete response letter from the US FDA relating to its AVT02 proposed adalimumab biosimilar rival to Humira. The latest BsUFA goal date disclosed for the product is now just a few days ahead of a potential US launch.
The Swiss biotech says the ERADICATE trial shows areas of differentiation for the antibiotic, like utility in pneumonia and across gram-negative and gram-positive bacteria.